Galapagos’ service companies, BioFocus and Argenta, have entered into a multi-year collaboration with AstraZeneca to find new compounds against key targets in AZ’s research programs in respiratory and inflammatory diseases.

BioFocus or Argenta will provide the medicinal chemistry, biology and ADME/PK services, and each AZ project will have access Argenta’s full suite of in vivo respiratory pharmacology models. Financial terms were not disclosed.

“Both BioFocus and Argenta have worked extensively with AstraZeneca during the past 10 years, and this new collaborative agreement brings enormous capability and experience to each AstraZeneca project we work on. We are delighted to renew our new drug discovery alliance with one of the world’s leading research-based pharmaceutical companies,” said Dr. Chris Newton, senior vice president of Galapagos Services.

“We continue to be impressed by the strength of the BioFocus and Argenta technology platforms and the evident depth of experience of the scientists that will be engaged on our projects addressing respiratory and inflammatory conditions,” said Dr. John Steele, vice president R&I Innovative Medicines Science Unit at AstraZeneca.